Evidence map›Paper›PMID 34865321›Full record

Observational studyThoracic cancer2022

Risk factors for in-hospital mortality in patients with advanced lung cancer with interstitial pneumonia undergoing systemic chemotherapy: A retrospective and observational study using a nationwide administrative database in Japan.

Tomoko Shiraishi, Keishi Oda, Kei Yamasaki, Takashi Kido, Konomi Sennari, Hiroshi Mukae, Makoto Ohtani, Yoshihisa Fujino, Shinya Matsuda, Kiyohide Fushimi and 1 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Tomoko ShiraishiDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Keishi OdaDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Kei YamasakiDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.ORCID 0000-0003-1876-3287
Takashi KidoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Konomi SennariDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Makoto OhtaniInformation Systems Center, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Yoshihisa FujinoDepartment of Environmental Epidemiology, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Shinya MatsudaDepartment of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Kiyohide FushimiDepartment of Health Policy and Informatics, Tokyo Medical and Dental University, Tokyo, Japan.
Kazuhiro YateraDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
University of Occupational and Environmental Health Japan · JPNagasaki University · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe safety profile of systemic chemotherapy for lung cancer patients with interstitial pneumonia (IP) in clinical practice remains unclear. Using Diagnostic Procedure Combination (DPC) data from the Japanese administrative database, we investigated the mortality of hospitalized lung cancer patients with IP as they underwent a course of systemic chemotherapy nationwide.

methodsThe DPC data of patients with stage IIIB or IV lung cancer as defined by the Union for International Cancer Control Tumor-Nodes-Metastases 6th and 7th editions from April 2014 to March 2016 were obtained. Among those patients, only patients with concomitant IP and receiving systemic chemotherapy without radiotherapy were included.

resultsAmong 1524 included patients, 70 (4.6%) died in the hospital. Multivariate analysis revealed that low activities of daily living (ADL) scores on admission (hazard ratio [HR] 2.26, 95% confidence interval [CI] 1.24-4.12, p = 0.008) and high-dose corticosteroid therapy following chemotherapy (HR 2.62, 95% CI 1.44-4.77, p = 0.002) were strongly associated with in-hospital mortality. It was determined that patients possibly received high-dose corticosteroids for IP exacerbations; these patients had a higher in-hospital mortality rate of 67.7% (21/31 patients) and a significantly shorter median survival time of 55 days (95% CI 31-69 days, p < 0.001) than those who did not receive high-dose corticosteroids.

conclusionAcute exacerbation of IP treated with systemic high-dose corticosteroids is significantly associated with in-hospital mortality, and a low ADL score on admission is a risk factor for in-hospital mortality in lung cancer patients with IP who undergo systemic chemotherapy.

Indexed as

Hospital MortalityAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDatabases, FactualFemaleHumansJapanLung Diseases, InterstitialLung NeoplasmsMaleMiddle AgedRetrospective StudiesRisk FactorsYoung Adultactivities of daily livingchemotherapyin-hospital mortalityinterstitial pneumonialung cancer

Identifiers

PMID34865321
PMCPMC8758426
OpenAlexW4200091437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.